A cancer drug targets two proteins in ovarian and endometrial tumors. Its first patient has been dosed.

ArriVent BioPharma dosed the first U.S. patient in a Phase 1 trial of ARR-002, a dual-target ADC for ovarian and endometrial cancer. Preclinical data showed ARR-002 outperformed bivalent ADCs. ArriVent licensed ARR-002 to Shanghai Allist for Greater China in August 2026.

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerat

ArriVent BioPharma (AVBP) dosed the first patient in a Phase 1 trial for ARR-002, an antibody-drug conjugate targeting ovarian and endometrial cancers. The trial evaluates safety, tolerability, and efficacy. ARR-002 targets MUC16 and NaPi2b proteins, with preclinical data showing improved activity. ArriVent licensed ARR-002 to Shanghai Allist Pharmaceuticals for Greater China.

ArriVent BioPharma (AVBP) has dosed the first patient in a Phase 1 trial of ARR-002, a treatment for ovarian and endometrial cancer. This marks an early-stage clinical milestone for the company's pipeline.

HC Wainwright & Co. kept a Buy rating and $27 price target on ArriVent BioPharma, implying a 59.9% upside from its Oct 7 close. The firm cited positive clinical data from the FURVENT trial and promising pipeline developments, including ARR-217, for its outlook.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.